Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety and Tolerability of BI 1584862 in Participants With Hepatic Impairment
NCT06957756Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1584862 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point up to 4 days and Maximum measured concentration of the analyte in plasma up to 4 days. Started Aug 2025; status: completed.
02
Drugs
BI 1584862
Beyond the preview
Go deeper on NCT06957756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957756.